Literature DB >> 25263387

Intraductal carcinoma of the prostate: interobserver reproducibility survey of 39 urologic pathologists.

Kenneth A Iczkowski1, Lars Egevad2, Jun Ma3, Nicholas Harding-Jackson4, Ferran Algaba5, Athanase Billis6, Philippe Camparo7, Liang Cheng8, David Clouston9, Eva M Comperat10, Milton W Datta11, Andrew G Evans12, David F Griffiths13, Charles C Guo14, Seife Hailemariam15, Wei Huang16, Peter A Humphrey17, Zhong Jiang18, Hillel Kahane19, Glen Kristiansen20, Francisco G La Rosa21, Antonio Lopez-Beltran22, Gregory T MacLennan23, Cristina Magi-Galluzzi24, Jennifer Merrimen25, Rodolfo Montironi26, Adeboye O Osunkoya27, Maria M Picken28, Nagarjun Rao4, Rajal B Shah29, Jonathan H Shanks30, Steven S Shen31, Ossama W Tawfik32, Lawrence D True33, Theodorus Van der Kwast12, Murali Varma13, Thomas M Wheeler34, Debra L Zynger35, Natasha Sahr4, David G Bostwick3.   

Abstract

The diagnosis of intraductal carcinoma (IDC) of the prostate remains subjective because 3 sets of diagnostic criteria are in use. An internet survey was compiled from 38 photomicrographs showing duct proliferations: 14 signed out as high-grade prostatic intraepithelial neoplasia (HGPIN), 17 IDC, and 7 invasive cribriform/ductal carcinoma. Each image was assessed for the presence of 9 histologic criteria ascribed to IDC. Thirty-nine respondents were asked to rate images as (1) benign/reactive, (2) HGPIN, (3) borderline between HGPIN and IDC, (4) IDC, or (5) invasive cribriform/ductal carcinoma. Intraclass correlation coefficient was 0.68. There was 70% overall agreement with HGPIN, 43% with IDC, and 73% with invasive carcinoma (P < .001, χ(2)). Respondents considered 19 (50%) of 38 cases as IDC candidates, of which 5 (26%) had a two-thirds consensus for IDC; two-thirds consensus for either borderline or IDC was reached in 9 (47%). Two-thirds consensus other than IDC was reached in the remaining 19 of 38 cases, with 15 supporting HGPIN and 4 supporting invasive carcinoma. Findings that differed across diagnostic categories were lumen-spanning neoplastic cells (P < .001), 2× benign duct diameters (P < .001), duct space contours (round, irregular, and branched) (P < .001), papillary growth (P = .048), dense cribriform or solid growth (both P = .023), and comedonecrosis (P = .015). When the 19 of 38 images that attained consensus for HGPIN or invasive carcinoma were removed from consideration, lack of IDC consensus was most often attributable to only loose cribriform growth (5/19), central nuclear maturation (5/19), or comedonecrosis (3/19). Of the 9 histologic criteria, only 1 retained significant correlation with a consensus diagnosis of IDC: the presence of solid areas (P = .038). One case that attained IDC consensus had less than 2× duct enlargement yet still had severe nuclear atypia and nucleomegaly. Six fold nuclear enlargement was not significant (P = .083), although no image had both 6× nuclei and papillary or loose cribriform growth: a combination postulated as sufficient criteria for IDC. Finally, 20.5% of respondents agreed that an isolated diagnosis of IDC on needle biopsy warrants definitive therapy, 20.5% disagreed, and 59.0% considered the decision to depend upon clinicopathologic variables. Although IDC diagnosis remains challenging, we propose these criteria: a lumen-spanning proliferation of neoplastic cells in preexisting ducts with a dense cribriform or partial solid growth pattern. Solid growth, in any part of the duct space, emerges as the most reproducible finding to rule in a diagnosis of IDC. Comedonecrosis is a rarer finding, but in most cases, it should rule in IDC. Duct space enlargement to greater than 2× the diameter of the largest, adjacent benign spaces is usually present in IDC, although there may be rare exceptions.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cribriform; High-grade prostatic intraepithelial neoplasia; Interobserver variability; Intraductal carcinoma; Prostate; Solid; Survey

Mesh:

Year:  2014        PMID: 25263387     DOI: 10.1016/j.anndiagpath.2014.08.010

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  8 in total

Review 1.  Intraductal carcinoma of prostate (IDC-P): from obscure to significant.

Authors:  Ni Chen; Qiao Zhou
Journal:  Chin J Cancer Res       Date:  2016-02       Impact factor: 5.087

2.  Distinct DNA methylation alterations are associated with cribriform architecture and intraductal carcinoma in Gleason pattern 4 prostate tumors.

Authors:  Ekaterina Olkhov-Mitsel; Farshid Siadat; Ken Kron; Liyang Liu; Andrea J Savio; John Trachtenberg; Neil Fleshner; Theodorus van der Kwast; Bharati Bapat
Journal:  Oncol Lett       Date:  2017-05-09       Impact factor: 2.967

Review 3.  [Intraductal carcinoma of the prostate].

Authors:  G Kristiansen; M Varma; G Seitz
Journal:  Pathologe       Date:  2016-02       Impact factor: 1.011

4.  Comedonecrosis Revisited: Strong Association With Intraductal Carcinoma of the Prostate.

Authors:  Samson W Fine; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; Satish K Tickoo; Victor E Reuter
Journal:  Am J Surg Pathol       Date:  2018-08       Impact factor: 6.394

Review 5.  Cribriform Patterned Lesions in the Prostate Gland with Emphasis on Differential Diagnosis and Clinical Significance.

Authors:  Maria Destouni; Andreas C Lazaris; Vasiliki Tzelepi
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

6.  Interchangeability of light and virtual microscopy for histopathological evaluation of prostate cancer.

Authors:  Renata Zelic; Francesca Giunchi; Luca Lianas; Cecilia Mascia; Gianluigi Zanetti; Ove Andrén; Jonna Fridfeldt; Jessica Carlsson; Sabina Davidsson; Luca Molinaro; Per Henrik Vincent; Lorenzo Richiardi; Olof Akre; Michelangelo Fiorentino; Andreas Pettersson
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

7.  The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma.

Authors:  Geert J L H van Leenders; Theodorus H van der Kwast; David J Grignon; Andrew J Evans; Glen Kristiansen; Charlotte F Kweldam; Geert Litjens; Jesse K McKenney; Jonathan Melamed; Nicholas Mottet; Gladell P Paner; Hemamali Samaratunga; Ivo G Schoots; Jeffry P Simko; Toyonori Tsuzuki; Murali Varma; Anne Y Warren; Thomas M Wheeler; Sean R Williamson; Kenneth A Iczkowski
Journal:  Am J Surg Pathol       Date:  2020-08       Impact factor: 6.298

8.  Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate.

Authors:  Mame-Kany Diop; Roula Albadine; André Kougioumoutzakis; Nathalie Delvoye; Hélène Hovington; Alain Bergeron; Yves Fradet; Fred Saad; Dominique Trudel
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.